Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Gains from Investment Securities (2020 - 2025)

Foghorn Therapeutics (FHTX) has 4 years of Gains from Investment Securities data on record, last reported at $1.2 million in Q2 2025.

  • For Q2 2025, Gains from Investment Securities rose 69.65% year-over-year to $1.2 million; the TTM value through Jun 2025 reached $1.3 million, down 50.06%, while the annual FY2024 figure was $860000.0, 75.78% down from the prior year.
  • Gains from Investment Securities reached $1.2 million in Q2 2025 per FHTX's latest filing, up from $4000.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $1.7 million in Q2 2023 and bottomed at $4000.0 in Q1 2025.
  • Average Gains from Investment Securities over 3 years is $623444.4, with a median of $705000.0 recorded in 2024.
  • Peak YoY movement for Gains from Investment Securities: crashed 94.57% in 2024, then soared 69.65% in 2025.
  • A 3-year view of Gains from Investment Securities shows it stood at $865000.0 in 2023, then plummeted by 94.57% to $47000.0 in 2024, then skyrocketed by 2444.68% to $1.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Gains from Investment Securities were $1.2 million in Q2 2025, $4000.0 in Q1 2025, and $47000.0 in Q4 2024.